NetworkNewsBreaks – MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) Receives Regulatory Green Light for Clinical Trial of Pancreatic Cancer Candidate
MabVax Therapeutics (NASDAQ: MBVX) is trading higher after announcing it has received authorization from the FDA for the initiation of a phase I clinical trial with MVT-1075 as a therapeutic treatment for pancreatic cancer. MVT-1075 is the company's novel, fully human antibody radioimmunotherapy. In this initial phase I trial the company plans to evaluate the safety, dosimetry, and pharmacokinetics of MVT-1075 with patient disease status evaluated based on tumor measurements using RECIST 1.1 criteria. The company intends to initiate the phase I clinical trial in the first half of 2017. "We are executing on the development strategy we have outlined…







